GLP-1 research is often discussed through the lens of weight loss, but that is only one visible endpoint. The broader clinical conversation is moving toward metabolic health: liver fat, A1C, inflammatory markers, cardiovascular outcomes, kidney-related endpoints, body composition, and how those signals connect across different study populations.

For BetterBio education, the point is not to turn clinical data into use advice. The point is to help readers ask better questions. What endpoint was measured? Was the outcome driven only by weight change, or did the study show signals beyond weight? Was the population diabetic, non-diabetic, living with established cardiovascular disease, or enrolled for liver histology?